Eli Lilly acquisitions: every deal in 2026
The mergers, acquisitions and takeovers Eli Lilly has announced, agreed or completed in 2026, newest first, each with its value, status and sources.
9Deals tracked
$16bnDisclosed value
$6.3bnLargest deal
6Completed
Eli Lilly acquisitions: every deal in 2026
- 31 Aug 2026Lilly agrees up to US$2.9bn deal for Merida BiosciencesEli Lilly and Company → Merida BiosciencesHealthcare / BiotechAgreedUndisclosed
- 16 Jul 2026Lilly completes AtaiBeckley takeover worth up to US$3.8bnEli Lilly and Company → AtaiBeckley Inc.Healthcare / BiotechCompleted$2.8bn
- 26 May 2026Lilly agrees deal worth up to US$1.5bn for shingles vaccine maker CurevoEli Lilly and Company → Curevo, Inc.Healthcare / VaccinesAgreedUndisclosed
- 26 May 2026Lilly agrees up-to-US$780m deal for Swiss vaccine maker LimmaTechEli Lilly and Company → LimmaTech Biologics AGHealthcare / VaccinesAgreedUndisclosed
- 27 Apr 2026Lilly agrees up-to-US$2.3bn deal for JAK2 specialist AjaxEli Lilly and Company → Ajax Therapeutics, Inc.Healthcare / BiotechCompletedUndisclosed
- 20 Apr 2026Lilly agrees up-to-US$7bn deal for in vivo CAR-T developer KeloniaEli Lilly and Company → Kelonia Therapeutics, Inc.Healthcare / BiotechCompleted$3.3bn
- 31 Mar 2026Lilly agrees up to US$7.8bn deal for CentessaEli Lilly and Company → Centessa Pharmaceuticals plcHealthcare / BiotechCompleted$6.3bn
- 9 Feb 2026Lilly agrees up to US$2.4bn deal for Orna TherapeuticsEli Lilly and Company → Orna Therapeutics, Inc.Healthcare / BiotechCompleted$2.4bn
- 7 Jan 2026Lilly agrees US$1.2bn deal for Ventyx BiosciencesEli Lilly and Company → Ventyx Biosciences, Inc.Healthcare / BiotechCompleted$1.2bn